Skip to main content

Treatment Clinical Trials for Gallbladder Cancer

Review the gallbladder cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 25

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Status: Active
Location: 15 locations
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Status: Active
Location: 12 locations
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Status: Active
Location: 11 locations
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Status: Active
Location: 5 locations
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Status: Active
Location: 4 locations
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Status: Active
Location: 4 locations
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Status: Active
Location: 3 locations
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Status: Active
Location: 2 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
Chemoimmunotherapy Combined with Deep Hyperthermia and Spatially-fractionated Radiotherapy for the Treatment of Advanced Biliary Tract Cancer
Status: Active
Location: 2 locations
Evaluating Response to Atezolizumab and Bevacizumab Treatment in Patients with Gastrointestinal Cancers and Minimal Residual Disease using ctDNA
Status: Active
Location: MedStar Georgetown University Hospital, Washington, District of Columbia
Gemcitabine, Cisplatin, and Pembrolizumab before and after Surgery for the Treatment of Potentially Resectable Biliary Tract Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Y-90 SIRT in Combination with Durvalumab and Gemcitabine and Cisplatin for the Treatment of Locally Advanced, Unresectable, or Metastatic Biliary Tract Cancer
Status: Active
Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Trifluridine/Tipiracil plus Oxaliplatin for the Treatment of Advanced or Metastatic Biliary Tract Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating with Pemigatinib for the Treatment of Unresectable, Locally Advanced or Metastatic Biliary Tract Cancers with FGFR2 Alterations
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Ligufalimab and Cadonilimab for the Treatment of Advanced Hepatobiliary Cancers
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Sequential Cytoreductive Interventions for the Treatment of Patients with Metastatic Digestive System Adenocarcinoma with Undetectable ctDNA
Status: Active
Location: Yale University, New Haven, Connecticut
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination with Gemcitabine, Cisplatin and Durvalumab for the Treatment of Biliary Tract Cancer Patients with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Emavusertib in Combination with Cisplatin, Gemcitabine, and Durvalumab for the Treatment of Advanced Unresectable or Metastatic Biliary Tract Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma
Status: Active
Location: See ClinicalTrials.gov
Cell Therapy (Tumor Infiltrating Lymphocytes) and Aldesleukin in Treating Patients with Locally Advanced, Recurrent, Refractory, or Metastatic Biliary Tract Cancers
Status: Temporarily Closed to Accrual
Location: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania